Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-26
2009-02-03
Weber, Jon P (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S825000
Reexamination Certificate
active
07485624
ABSTRACT:
Methods for treating cardiac muscle disorders, such as cardiac arrhythmias, by administration of a neurotoxin to cardiac muscle are disclosed. Bradycardia can be alleviated for several months by a single intrapericardial or intracardiac injection or infusion of a botulinum toxin. Tachycardia can be alleviated by preganglionic sympathetic nervous system administration of a botulinum toxin.
REFERENCES:
patent: 4920116 (1990-04-01), Morgan, Jr. et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5865794 (1999-02-01), Castro
patent: 6623742 (2003-09-01), Voet
patent: 6767544 (2004-07-01), Brooks et al.
patent: 6869610 (2005-03-01), Aoki et al.
patent: WO 9517904 (1995-07-01), None
Lamanna et al., “Cardiac effects of botulinal toxin,” Arch Int Pharmacodyn 293:69-83, 1988.
Waxman et al., “Persistent primary coronary dilation induced by transatrial delivery of nitroglycerin into the pericardial space: a novel approach for local cardiac drug delivery,” J Am Coll Cardiol 33(7):2073-2077, 1999.
KSR international Co.v.Teleflex Inc. et al., 550 US—(2007), Apr. 30, 2007.
Sauviat, M.-P., “Modulation muscarinique de l'activite cardiaque,” J Soc Biol 193(5):469-480, 1999.
Dickson, E.,Studies on the Manner in which the Toxin of Clostridium Botulinum Acts Upon the Body, J. Exper Med 37: 711-31 (1923) d.
Braunwald, E.,Heart Disease A Textbook of Cardiovascular Medicine, fifth edition (1997), two volumes, W.B. Saunders Company.
Opie, L.,Drugs for the Heart, fourth edition (1997), W.B. Saunders Company.
Fauci, A.,Harrison's Principles of Internal Medicinefourteenth edition (1997), McGraw Hill.
Nattel, S.,Comparative Mechanisms of Acton on Antiarrhythmic Drugs, Am J. Cardiol, 72: 13F-17F (1993).
Wit, A.,Electrophysiological Basis for Antiarrhythmic Drug Action, Clin. Physiol. Biochem. 3: 127-134 (1985).
Waxman, S.,Persistent Primary Coronary Dilation Induced by Transatrial Delivery of Nitroglycerin into the Pericardial Space: A Novel Approach for Local Cardiac Drug Delivery, J Am Coll Cardiol 33: (7); 2073-2077 (1999).
Claus, D.,Botulinum Toxin: Influence on Respiratory Heart rate Variation, Mov Disord 10(5): 574-9 (1995).
Kimura, K.,Negative Chronotropic Effect of Botulinum Toxin on Neonatal Rat Cardiac Myocytes, Biochem Biophys Res Commun 6; 244 91): 275-9 (1998).
Nebe, A.,No Effects on Heart-Rate Variability and Cardiovascular Reflex Tests After Botulinum Toxin Treatment of Cervical Dystonia, Mov Disord; 11 (3): 337-9 (1996).
Glaradi, G.,The Local Injection of Botulinum Toxin can Affect the Neural Control of Heart Rate Variability, Neural 44; (Sup 2): A307-A308 (1994).
Laham, R.,Therapeutic Myocardial Angiogenesis Using Percutaneous Intrapericardial Drug Delivery, Clin Cardiol; 22 (supp 1): 16-19 (1999).
Laham, R.,Subxyphoid Access of the Normal pericardium: A Novel Drug Delivery Technique, Cath&Cardiovasc Inter 47:109-111 (1999).
Sonobe, T.,Development of Intracoronary Local Adhesive delivery Technique, Int. J Artic Organs 20(6); 319-326 (1997).
Avitall, B.,Iontophoretic Transmyocardial Drug Delivery. A Novel Approach to Antiarrhythmic Drug Therapy, Circulation 85: 1582-93 (1992).
Ayer GM,Amiodarone Instilled into the Canine Pericardial Sac Migrates Transmurally to Produce Electrophysiologic Effects and Suppress Atrial FibrillationJ Cardiovasc Electrophysiol 7: 713-21 (1996).
Labhasetwar V.,Epicardial Administration of Ibutilide from Polyurethane Matrices: Effects on Defibrillation Threshold and Electrophysiologic ParametersJ Cardiovasc Pharmacol 24: 826-40 (1994).
Lambert, C.,Local Drug Delivery, Cath & Cardiovasc Diagn 41: 231 (1997).
Glazier, J.,Site-Specific Intracoronary Thrombolysis With Urokinase-Coated Hydrogel Balloons: Acute and Follow-Up Studies in 95 Patients, Cath & Cardiovasc Diagn 41: 246-253 (1997).
Bartorelli, A.,Local Heparin Delivery Prior to Coronary Stent Implantation: Acute and Six Month Clinical And Angiographic Results, Cath & Cardiovasc Diagn 42: 313-320 (1997).
Nebe, A.,Influence of Botulinum Toxin Type A on the Heart Rate Variability in Patients with Cervical Dystonia, Mov Dis 10; 3: 389 (1995).
Claus, D.,Distant Effects of Botulinum Toxin on Autonomic Cardiac Reflexes, Mov Dis 10: 3: 389 (1995).
Thomas, C.,Local Intracoronary Heparin Delivery With a Microporous Balloon Catheter, Amer Heart J 132; 5: 969-972 (1996).
Camemzind, E.,Site-Specific Intravascular Administration of drugs: History of a Method Applicable in Humans, Cath & Cardiovasc Diagn 41: 342-347 (1997).
Lamanna, C., et al.; Cardiac Effects of Botulinal Toxin;Arc Int. Pharmacodyn.; 1988; vol. 293; 69-83.
McDermott, D.A., et al.; Use of an Indwelling Catheter for Examining Cardiovascular Responses to Pericardial Administration of Bradykinin in Rat;Cardiovascular Research; 1995; vol. 30; 39-46.
Kimura et al.,; “Negative Chronotropic Effect of Botulinal Toxin on Neonatal Rat Cardiac Mycocytes. . . ” Biochem. Biophys. Res. Comm., vol. 244, 1998, pp. 275-279.
Sauviat M-P.: “Effect of Neurotoxins on the Electrical and Mechanical Activity of Heart Muscle”,Comptes Rendus Des Seances De La Societe De Biolobie Et De Ses Filiales., vol. 191, 1997, pp. 451-471.
Johnson, Eric; Clostridial Toxins as Therapeutic Agents; Benefits of Nature's Most Toxic Proteins,Annu Rev Microbiol53: 551-575, 1999.
Schmitt et al.; “Bacterial toxins: friends or foes?”Emerg Infect Dis5(2): 224-234, 1999.
Tsuboi et al.; “Botulinum Neurotoxin A Blocks Cholinergic Ganglionic Neurotransmission in the Dog Heart”. Jpn J. Pharmacol 89 (3); 249-254, 2002.
Tsuboi et al.; “Inotropic Chronotropic and Dromotropic Effects Mediated Via Parasympathetic Ganglia in the Dog Heart.”Am J Physiol Heart Circ Physiol279: H1201-H1207, 2000.
Mangrum et al., “The Evaluation and Management of Bradycardia”.N Eng J Med342(10): 703-709, 2000.
Allergan Inc.
Donovan Stephen
Kosson Rosanne
Nassif Claude L.
Voet Martin
LandOfFree
Method for treating cardiac muscle disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cardiac muscle disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cardiac muscle disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4094492